Immunocore is a biotechnology company developing T-cell receptor (TCR) bispecific therapies that redirect immune cells to attack cancer and other diseases. Its lead commercial product, Kimmtrak (tebentafusp), is approved for metastatic uveal melanoma and is built on the company’s ImmTAC platform. The pipeline extends TCR-based candidates into other solid tumors and beyond oncology.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 93.9 | — | 5 | — |
| Q2 2025 | 98 | — | -10.3 | — |
| Q3 2025 | 103.7 | — | -0.2 | -102.1% |
| Q4 2025 | 104.5 | — | -30.1 | — |
| Q1 2026 | 106.7 | 13.6% | 13 | 158.2% |
| Q2 2026 | 115.9 | 18.3% | -0.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Target Hospitality Corp. (TH), uniQure N.V. (QURE), Ocular Therapeutix, Inc. (OCUL), Structure Therapeutics Inc. (GPCR), Innoviva, Inc. (INVA), Dorchester Minerals, L.P. (DMLP)